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Abstract
Glutamine has been launched as a conditionally
indispensible amino acid for the critically ill.
Supplementation has been recommended in
guidelines from international societies. Although
data have been presented pointing out that
glutamine supplementation may not be for everybody,
recommendations for treatments and design of study
protocols have included all critically ill patients. Results
from more recent studies and meta-analyses indicate
that indiscriminate use of glutamine supplementation in
critically ill patients may actually cause harm rather than
beneficial effects. This viewpoint sorts out arguments of
controversy in the glutamine story.
Keywords: Hypoglutaminemia, Hyperglutaminemia,
Critical care, Guidelines
Glutamine is not for everybody, but possibly for
some
The glutamine story is over in the sense that the hypoth-
esis that all critically ill patients should be given extra
glutamine supplementation has been demonstrated not
to be valid [1–4]. However, the hypothesis that some
critically ill patients may have a shortage of glutamine
which needs to be corrected has not been tested appro-
priately [3, 4]. Originally a hypothesis of glutamine being
conditionally essential in critical illness was launched [5, 6].
Although it was never proposed that this condition was a
general feature of critical illness, the idea of glutamine
supplementation was embraced for general use, not con-
fined to patients with hypoglutaminemia only.
When glutamine supplementation studies are put
together into meta-analyses, there is no longer a recom-
mendation for general use in the critically ill. It is pointed
out that studies involving patients on enteral nutrition
and with an enterally administered supplementation are
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less likely to show beneficial effects from glutamine
supplementation [7–10]. However, when separating
studies employing glutamine supplementation by the
parenteral route only, there is still one meta-analysis
advocating the use of glutamine supplementation in
this setting [9].
For many years it has been known that a low plasma
glutamine concentration at ICU admission is associated
with an unfavorable outcome [11, 12]. It is also demon-
strated that hypoglutaminemia is not connected to
mortality risk predictors such as APACHE II or SAPS.
Hypoglutaminemia at ICU admission is actually an inde-
pendent mortality predictor, adding mortality prediction
accuracy to the APACHE II in consecutive unselected
patients admitted to the ICU [12].
From existing data we know that hypoglutaminemia is
not a particular feature of the sickest ICU patients
[11, 12]. On the contrary, admission plasma glutam-
ine is totally unrelated to mortality predictors such as
APACHE II or SAPS III. Recruitment of only the very
sickest patients for glutamine supplementation to
counteract hypoglutaminemia is therefore not sup-
ported by the existing observational data.
The recruitment of ICU patients with severe sepsis
and two or more organ failures to receive a very high
dose of combined enteral and parenteral supplementa-
tion was therefore not a good idea [13]. Although there
may be a selection bias in the recruitment [14, 15], the
message from this study is very clear—there is no benefi-
cial effect of indiscriminate glutamine supplementation,
and there is perhaps harm [13]. There are three import-
ant remaining questions: (i) might harm be associated
with administration of supraphysiologic doses of exogen-
ous glutamine during hypocaloric nutrition; (ii) if so,
what is the underlying mechanism; and (iii) might there
be a subgroup of patients who benefit from glutamine
supplementation?
It is of course important to point out that the statis-
tical connection between hypoglutaminemia and an
unfavorable outcome fulfills the criteria for a biomarker,
but provides no proof of a causal connection. Launching
the hypothesis that exogenous supplementation to
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achieve normoglutaminemia and thereby improve out-
comes is not far-fetched, but this hypothesis is still to be
proven. In all studies with a beneficial effect, the absence
of a statistical connection between a change in plasma
glutamine concentration and the advantage achieved is a
clear limitation. If treatment of hypoglutaminemia
should be the primary target for glutamine supplementa-
tion, the connection between plasma concentration and
beneficial effects must be much better described.
Alongside the observational data associating hypoglu-
taminemia at ICU admission with unfavorable outcome,
there is massive evidence that low abundance of glutam-
ine in experimental systems and in animals is associated
with low performance, in particular of the immune
system and of the intestinal mucosa [16, 17]. Some of
the reported effects are responses to glutamine supple-
mentation outside the physiologic range, but on the
contrary there were no reports of harmful or toxic
effects at supraphysiologic levels. The idea to provide
glutamine supplementation to all patients regardless of
documented hypoglutaminemia was therefore embraced
by a large number of investigators. The motivation
behind not including glutamine plasma levels was often
the difficulty in obtaining emergency plasma glutamine
concentration determinations, and the perhaps erroneous
idea that extra glutamine was not toxic.
Plasma glutamine as proxy
Can the plasma glutamine concentration guide us (Fig. 1)?
In general we know that there is a poor correlation be-
tween plasma concentration and tissue concentrations
[18–21]. Following elective surgery of moderate size there
is a drop in muscle but not in plasma [19]. In critically ill
subjects, on the contrary, there is a profound drop in
muscle while the drop in plasma is variable, and always
less dramatic [18, 20]. In other tissues like the intestinal
mucosa, the tissue concentration and plasma concentration
are more or less parallel during critical illness, and the
gradient does not change as it does in muscle [22]. The glu-
tamine plasma concentration is therefore not a perfect
reflection of total glutamine availability; it is a low fraction
of the total free glutamine pool, and the equilibration in the
total free glutamine pool is very slow [23].
The relation between hypoglutaminemia and an un-
favorable outcome is confined to the admission value of
plasma glutamine [12, 24]. Beyond this, knowledge is
scattered. The glutamine concentration at admission to
the ward after an ICU stay > 96 hours does not predict
outcome [24]. Among extreme ICU longstayers, a high
plasma glutamine concentration is associated with poor
outcome [25], but general hyperaminoaciemia and high
concentrations of other amino acids were even stronger
indicators of a poor outcome, so this particular observa-
tion was not specific for glutamine. In the study cited,
the plasma concentration during ongoing IV glutamine
supplementation was in the reference range, but values
in the higher part of normal glutamine concentration
interval added mortality prediction to the admission
SAPS III [24]. Another report finds a high plasma glu-
tamine level on day 8 of an ICU stay to correlate with 6-
month mortality, regardless of whether enteral glutam-
ine supplementation was given or not and regardless of
admission mortality prediction [26]. In summary, there
is therefore little evidence that the plasma glutamine
concentration during ICU stay and post ICU stay can
serve as an outcome predictor. Hyperglutaminemia is pos-
sibly associated with a poor outcome, which may be a part
of general hyperaminoacidemia.
The low muscle free glutamine concentration in crit-
ical illness is probably a general phenomenon, although
there are no reports of muscle glutamine in consecutive
admissions [18]. This is in contrast to hypoglutaminemia
in the critically ill, which occurs in only 1/3 of ICU
admissions, and is not related to admission mortality
prediction scores, although it adds predictive value to
such scores [12].
The only patient group reported with hyperglutamine-
mia is those with acute liver failure [27]. Furthermore, in
a study of consecutive patients admitted to the ICU, an
association between hyperglutaminemia at ICU admit-
tance and an unfavorable outcome was seen [12]. On the
contrary, no general connection between hyperglutami-
nemia at ICU admission and an unfavorable outcome
could be demonstrated in a selected population of only
patients with liver failure [28].
Recently a high plasma glutamine concentration dur-
ing critical illness has been suggested to be an ominous
prognostic sign [2]. These data are less consistent com-
pared with the data behind the original hypothesis
involving hypoglutaminemia at ICU admittance. It has
been clearly demonstrated that the plasma glutamine
Fig. 1 Updated summary of glutamine plasma concentration as a
biomarker. iv intravenous
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concentration in ICU survivors 24 h after ICU discharge
is most often in the normal range and has no predictive
value for outcomes [24]. In the same study it was ob-
served that the plasma glutamine concentration during
ongoing IV glutamine supplementation on the last day
of the ICU stay was in the normal range, but was statis-
tically associated with post-ICU mortality [24]. This
association also remained when the ICU discharge SOFA
score was used as an outcomes predictor. A post-hoc
finding when ICU patients were randomized to a glu-
tamine-containing enteral product was that an
increase in plasma glutamine from ICU admission to
day 8 of the ICU stay was associated with 6-month
mortality [1]. Taken together these reports offer no
clear picture, but call for a more systematic explor-
ation of the relation between plasma glutamine con-
centration and outcomes during critical illness, with
and without exogenous supplementation.
What is the substance behind the hypothesis that
hypoglutaminemia is an indicator of glutamine shortage
and therefore an indication for substitution. Is hypoglu-
taminemia an indication of low free glutamine levels in
tissues? In critical illness this is true for muscle, but not
for intestinal mucosa, although the reverse (low tissue
means low plasma) is not necessarily true [22]. Is hypo-
glutaminemia an indicator of low peripheral export of
glutamine to the splanchnic organs? In the very few pub-
lications on this issue, there is no obvious connection
[29]. Is hypoglutaminemia an indicator of low de-novo
glutamine production? Again, very limited information,
but so far no connection has been observed between
muscle glutamine synthase activity or free glutamine Ra
and low plasma glutamine [30]. In summary, there is no
obvious connection between hypoglutaminemia at ICU
admission and signs of glutamine shortage, which does
not rule out glutamine supplementation as a good idea
but does not supply the hypothesis with a rational
argument.
Possible underlying mechanisms of harm and effect
Supplementation of glutamine may be administered by
IV or enteral route, which is a both confusing and con-
troversial topic. When identical doses of glutamine or a
glutamine-containing dipeptide are given, IV administra-
tion produces a much higher plasma concentration
compared with enteral administration [31, 32]. The
distribution of a given dose of supplementation will
therefore obviously differ in relation to the route of
administration. This is accounted for in several meta-
analyses, which present subgroup analyses according to
the route of administration [7–10]. Unfortunately, to
add to the confusion, the route for general administra-
tion of nutrition is not distinctively separated from the
route for glutamine administration. Commonly in critically
ill patients, nutrition is administered as a combination of
enteral and parenteral supply. Enteral nutrition was for a
long time considered superior to parenteral nutrition in
terms of morbidity and mortality outcomes. Unfortunately
most (if not all) of the studies behind this finding were
biased in terms of patient selection. When the two routes
of administration were prospectively compared in patients
eligible for both routes, there were no differences in
outcomes [33].
Studies with a parenteral administration of glutamine
(or glutamine-containing dipeptides) are in general exhi-
biting more beneficial results compared with studies
with enteral administration [7, 9]. The number of studies
with a combined enteral and parenteral supplementation
is low [13]. Is it reasonable to separate studies according
to the route of glutamine administration? If the target is
to achieve an effect upon plasma glutamine concentra-
tion—yes? If the target is to supply a certain amount of
glutamine—not self-evident. As already indicated, the
metabolic faith of administered glutamine will be differ-
ent according to the route of administration. The ques-
tion is whether this difference might be translated into a
difference in clinical outcomes.
It is known that the export of glutamine from muscle
tissue during critical illness is enhanced [29]. This export
is a reflection of the development of sarcopenia, well
known particularly in ICU longstayers [34, 35]. In a
small longitudinal study the volume of this export did
not change over time during the ICU stay [29]. This may
be interpreted as the glutamine export from muscle
being insufficient and therefore being a factor adding to
the need for a prolonged ICU stay. An alternative inter-
pretation may be that the longstayers with a maintained
glutamine export actually were the selected survivors.
Again, this calls for future studies to better understand
glutamine kinetics during critical illness.
In an effort to study the mechanism behind plasma
glutamine concentration and glutamine availability, the
endogenous production of glutamine was quantified in
terms of glutamine rate of appearance, a technique that
employs isotopic labeled glutamine [30]. In a limited
number of ICU patients there was no clear relationship
between the plasma concentration of glutamine and the
rate of appearance [36]. In addition, adding exogenous
IV glutamine supplementation actually increased the rate
of appearance. In summary, efforts to quantify glutamine
availability by measurement of the rate of appearance
will add information of glutamine kinetics during critical
illness and may add information concerning the mecha-
nisms behind beneficial effects as well as harm of
glutamine supplementation.
A possible harmful effect is also reported in studies
where extra glutamine supplementation is combined
with supplementation of other additives, such as
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arginine and omega-3 fatty acids [26]. These studies also
raise concern over extra glutamine supplementation, but
studies with several additives in parallel are most often
not conclusive. In general, studies combining several
active interventions are almost universally adding confu-
sion rather than new evidence.
Are further studies over glutamine supplementation
motivated?
So what is agreed upon? Indiscriminate use of extra glu-
tamine supplementation for all critically ill patients is no
longer on the agenda. On the contrary, nobody is advo-
cating a glutamine-free diet for critically ill patients—but
that is probably the end of agreement. All available
enteral products for ICU nutrition contain glutamine,
being a natural constituent of proteins, usually 7–8 % of
the amino acid content. Simultaneously, conventional
nutritional products for parenteral use do not contain
glutamine due to glutamine instability in aqueous solu-
tion. Should the ideal parenteral product mimic the
enteral? This question is further complicated by the fact
that not all commercial sets of nutrition products con-
tain the option of a choice between glutamine-free and
glutamine-containing parenteral alternatives (on the
same level as in enteral products).
An adequate evaluation of the glutamine hypothesis
would be to supply patients with hypoglutaminemia at
ICU admission with a dose of glutamine that normalizes
plasma glutamine together with an adequate caloric and
protein supply, not less than 50 % of energy expenditure
and not less than 50 % of ESPEN-recommended protein
supply. Such a protocol would necessitate the use of IV
exogenous glutamine supplementation, because the
effect of enteral supplementation upon plasma concen-
tration is less predictable [26, 32, 37]. In addition, the
supplementation of glutamine is not likely to be effective
without being a part of optimal nutrition. Because this is
a highly controversial issue today, the design of the study
must consider the glutamine level, the caloric and
protein intakes and the timing.
The absence of any close relationship between plasma
glutamine concentration and the global glutamine status
of the individual patient remains problematic. The con-
nection between hypoglutaminemia at admission and
unfavorable outcome still points to this group of critic-
ally ill patients as the most suitable candidates for
supplementation.
The strongest argument for a prospective study is per-
haps the absence of any mechanistic explanation of the
harmful results, which is translated into a limited exter-
nal validity of these results [38]. This should be com-
pared with the results reported when critically ill
patients are fed according to estimated caloric needs;
results are then reported as beneficial or as no effect
without harm [39]. Still, a key question is whether the
plasma glutamine concentration might serve as a proxy
endpoint between exogenous supplementation and an
outcome-related endpoint. Such a proxy endpoint might
allow titration of the supply to individualized dosing.
Point-of-care instruments may be helpful when using
such a proxy endpoint [40].
Is there any agreement over the need to further
explore the subgroup of critically ill patients with hypo-
glutaminemia at ICU admission? This issue comes down
to whether hypoglutaminemia is a biomarker reflecting a
general shortage of physiologic reserve not fully covered
by the conventional risk scoring systems, or whether it
is a biomarker also reflecting a mechanistic role for glu-
tamine. Although everybody would agree that there is
insufficient solid knowledge, opinions remain apart.
Conclusion
The concept of glutamine as a conditionally indispen-
sible amino acid is dead, as is the concept of supple-
menting all critically ill patients. The hypothesis that
patients with hypoglutaminemia at ICU admittance
may benefit from IV supplementation to normalize
the plasma glutamine levels has never been tested.
Opinions deviate as to whether or not this hypothesis
is worthwhile to explore.
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